The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

The benefit from immune checkpoint inhibitors is tempered by immunologic toxicities, which
involve diverse organs, have varying biology, onset time, and severity. Herein, we identify …

Immune-checkpoint inhibitors (ICIs) have transformed patient care in oncology but are
associated with a unique spectrum of organ-specific inflammatory toxicities known as …

Immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI)
therapy may vary substantially in their clinical presentation, including natural history …

While the spectrum of neurological immune checkpoint inhibitor-related adverse events is
expanding, patients' outcomes are not well documented. This study aimed to assess …

Background Neurological immune-related adverse events (irAE-n) are severe and
potentially fatal toxicities of immune checkpoint inhibitors (ICI). To date, the clinical …

Paraneoplastic neurological syndromes (PNS) include any symptomatic and non-metastatic
neurological manifestations associated with a neoplasm. PNS associated with antibodies …

Aim Immune checkpoint inhibitor-induced encephalitis (ICI-iE) is a rare but life-threatening
toxicity of immune checkpoint inhibitor treatment. We aim to identify the characteristics of ICI …

Background and Objectives To clinically characterize post–immune checkpoint inhibitor (ICI)
Hu antibody (Ab) neurologic disorders, we analyzed Hu-Ab–positive patients with …

Objectives Population-based epidemiologic data for paraneoplastic neurologic syndromes
(PNSs) in the United States are lacking. Our objective was to evaluate the incidence …